Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FBL-XXX
- Development stage
- Unknown
- Lead developer
- Fable Therapeutics
- Administration
- Subcutaneous
01
Overview
FBL-XXX is a discovery-stage therapeutic candidate being developed by Fable Therapeutics (also known as Fable Biyoteknoloji). It is identified as an Fc fusion protein, a modality designed to extend the circulating half-life of therapeutic proteins and potentially engage immune system effector functions. While the specific biological target and therapeutic indications for FBL-XXX have not been publicly disclosed, the asset is part of Fable's pipeline focused on precision biologics for oncology and immunology. The company utilizes platforms such as Multiplexed Effector Cell Engagement (MECE) and Tailored Cytokine Activation (TCA) to engineer its candidates.
Beyond the preview
Go deeper on FBL-XXX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FBL-XXX.